Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, March 21, 2024
Lifenet and Eisai Co-Develop Dementia Insurance "be"
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
Wednesday, March 6, 2024
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
Wednesday, February 21, 2024
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Tuesday, February 20, 2024
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Friday, February 16, 2024
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Thursday, February 1, 2024
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
Friday, January 26, 2024
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
Thursday, January 18, 2024
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
Wednesday, January 17, 2024
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: